Clinical trial
A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With…
NCT00131352 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00131352 |
|---|---|
| Title | A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee |
| Official title | A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients With Symptomatic Osteoarthritis of the Knee |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Knee, Musculoskeletal Diseases |
| Intervention type | Device, Other |
| Interventions | hylan G-F 20, Phosphate Buffered Saline |
| Enrollment | 253 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 18, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Belgium, Czechia, France, Germany, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: